Better Therapeutics shares are trading higher after the FDA approved the company's AspyreRx prescription-only digital therapeutic treatment to provide cognitive behavioral therapy to adult patients with type 2 diabetes.
Portfolio Pulse from Benzinga Newsdesk
The FDA has approved Better Therapeutics' AspyreRx, a prescription-only digital therapeutic treatment providing cognitive behavioral therapy to adult patients with type 2 diabetes. This has led to a rise in the company's stock.
July 11, 2023 | 8:32 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Better Therapeutics' stock is trading higher following the FDA approval of its AspyreRx treatment for type 2 diabetes.
The FDA approval of a company's product generally leads to increased investor confidence, which can drive up the stock price. In this case, the approval of AspyreRx, a treatment for a widespread condition like type 2 diabetes, is likely to have a significant positive impact on Better Therapeutics' stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100